Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is a If channel inhibitor presented as an oral tablet for oral use. It is used to manage chronic heart failure and stable angina pectoris in adult patients. The drug reduces heart rate by selectively inhibiting the funny (If) current in the sino‑atrial node without affecting myocardial contractility or blood pressure.

GNH USA supplies Ivabradine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Ivabradine acts on the cardiac conduction system by lowering heart rate, and is indicated for the following conditions: - Chronic heart failure: improves symptoms, exercise tolerance and reduces hospitalization risk. - Stable angina pectoris: decreases frequency of angina attacks and need for nitroglycerin. - Heart failure with reduced ejection fraction: provides mortality benefit when combined with standard therapy.

Ivabradine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia - Visual disturbances (phosphenes) - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic severe bradycardia - Atrial fibrillation - Severe visual impairment - Allergic reactions such as rash or angioedema - QT interval prolongation

When prescribing Ivabradine, clinicians should observe the following precautions. - Cardiac monitoring: assess resting heart rate before initiation and periodically during therapy. - Contraindicated in severe hepatic impairment: avoid use in patients with Child‑Pugh class C liver disease. - Caution with sick sinus syndrome: do not use in patients with pre‑existing sinus node dysfunction. - Avoid concomitant strong CYP3A4 inhibitors: such as ketoconazole, clarithromycin, which can increase plasma levels. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Ivabradine interacts with several medicines; notable interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations and increase risk of bradycardia. - Other bradycardic agents (beta‑blockers, digoxin, verapamil): additive heart‑rate lowering effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine exposure. - Verapamil or diltiazem: moderate CYP3A4 inhibition, may require dose adjustment. - Antidepressants affecting CYP3A4 (e.g., fluoxetine): monitor for increased effects.